- Infectious disease drugs are essential in global healthcare, targeting pathogens such as bacteria, viruses, fungi, and parasites to prevent, treat, and manage infections, significantly impacting public health outcomes
- The escalating demand for infectious disease drugs is primarily fueled by the rising global prevalence of infectious diseases, including re-emerging infections and drug-resistant strains, and continuous advancements in drug discovery and diagnostic technologies
- North America dominates the infectious disease drug market with the largest revenue share of 38.14% in 2024, characterized by a well-developed healthcare sector, high healthcare expenditure, favorable reimbursement policies, and the strong presence of major pharmaceutical companies investing heavily in R&D
- Asia-Pacific is expected to be the fastest growing region in the infectious disease drug market during the forecast period due to its large patient population, increasing prevalence of infectious diseases, improving healthcare infrastructure, and rising government initiatives for disease prevention and treatment
- Viral Diseases segment dominates the infectious disease drug market with a market share of 43.63% in 2024, driven by its increasing prevalence of viral infections such as HIV, hepatitis, and influenza, coupled with the continuous emergence of new viral threats and significant advancements in antiviral drug development
